AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21481225 — intervention group
Group type: EXPERIMENTAL
Intervention: Milled rye kernel bread
Number of subjects: 44
Study 21481225 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye kernel breakfast
Number of subjects: 44
Study 21481225 — intervention group
Group type: COMPARATOR
Intervention: Sifted wheat bread (control)
Number of subjects: 44
Study 21481225 — intervention group
Group type: EXPERIMENTAL
Intervention: Milled rye kernel porridge
Number of subjects: 44
Study 18279549 — intervention group
Group type: COMPARATOR
Intervention: Diet C (increased consumption of cereals)
Number of subjects: 60
Study 18279549 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet V (increased consumption of vegetables)
Number of subjects: 60
Study 16511902 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal screening offered
Number of subjects: 0
Study 16511902 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive screening result
Number of subjects: 0
Study 16511902 — intervention group
Group type: COMPARATOR
Intervention: Negative screening result or declined screening
Number of subjects: 0
Study 12693793 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily budesonide/formoterol (160/4.5 microg, two inhalations)
Number of subjects: 523
Study 12693793 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily budesonide/formoterol (160/4.5 microg, one inhalation)
Number of subjects: 523
Study 12693793 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (400 microg) once-daily
Number of subjects: 523
Study 10711617 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution rinsed twice during 4 hours
Number of subjects: 8
Study 10711617 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution rinsed three times during 24 hours
Number of subjects: 8
Study 10711617 — intervention group
Group type: COMPARATOR
Intervention: Saline rinsed control
Number of subjects: 8
Study 8617089 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective digestion decontamination (SDD) using amphotericin B, colistin sulfate, and gentamicin applied every 6 hours
Number of subjects: 148
Study 8617089 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 148
Study 1399729 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 7506 (black patients)
Number of subjects: 1294
Study 1399729 — intervention group
Group type: COMPARATOR
Intervention: Protocols 7706 and 8307 (black patients)
Number of subjects: 1294
Study 3903382 — intervention group
Group type: EXPERIMENTAL
Intervention: Flatoril (dimethicone 200 mg and clebopride 0.5 mg)
Number of subjects: 0
Study 3903382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30616012 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicella vaccine
Number of subjects: 5997
Study 30616012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5997
Study 27918968 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral therapy with asynchronous therapeutic support
Number of subjects: 205
Study 26122037 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 500μW/cm2 of unfiltered LED light
Number of subjects: 20
Study 26122037 — intervention group
Group type: COMPARATOR
Intervention: Group B: 1500μW/cm2 LED light with blue-blocking glasses (achieving 500μW/cm2 at eye level)
Number of subjects: 20
Study 26122037 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after light exposure
Number of subjects: 20
Study 23492647 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB+D (losartan 50mg + hydrochlorothiazide 12.5mg)
Number of subjects: 140
Study 23492647 — intervention group
Group type: COMPARATOR
Intervention: ARB+C (amlodipine 5mg + typical dosage of ARBs)
Number of subjects: 140
Study 21486810 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich meal
Number of subjects: 10
Study 21486810 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 18690015 — intervention group
Group type: EXPERIMENTAL
Intervention: mpHBV (modified process hepatitis B vaccine)
Number of subjects: 860
Study 18690015 — intervention group
Group type: COMPARATOR
Intervention: RECOMBIVAX HB (control vaccine)
Number of subjects: 860
Study 18690015 — intervention group
Group type: EXPERIMENTAL
Intervention: mpHBV and RECOMBIVAX HB (control vaccine)
Number of subjects: 860
Study 16957573 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg/day for 3 months
Number of subjects: 22
Study 16957573 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment change)
Number of subjects: 22
Study 16957573 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 22
Study 12515990 — intervention group
Group type: EXPERIMENTAL
Intervention: Homecare hospice intervention
Number of subjects: 150
Study 11097593 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical proparacaine hydrochloride 0.5%
Number of subjects: 47
Study 11097593 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical flurbiprofen 0.03%
Number of subjects: 47
Study 11097593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 11097593 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to oleoresin capsicum (pepper spray)
Number of subjects: 47
Study 9024449 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP-guided treatment (group 1)
Number of subjects: 176
Study 9024449 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP-guided treatment (group 2a)
Number of subjects: 176
Study 9024449 — intervention group
Group type: COMPARATOR
Intervention: At least 5-day treatment (group 2b)
Number of subjects: 176
Study 1332213 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin administered subcutaneously once daily (200 U(anti‐FXa)/kg/24h)
Number of subjects: 101
Study 1332213 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin administered subcutaneously twice daily (100 U(anti‐FXa)/kg/12h)
Number of subjects: 101
Study 2948442 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF + HD-MPA
Number of subjects: 100
Study 2948442 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 100
Study 31765871 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching for Creativity Module (TCM) intervention, which included a 2-day workshop followed by 6 hours of reinforcement in the classroom over an 18-week capstone course.
Number of subjects: 42
Study 31765871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 42
Study 29471226 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to patient testimonials about Medical Cannabis (MC)
Number of subjects: 396
Study 29471226 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to narratives with external attribution of disease responsibility
Number of subjects: 396
Study 29471226 — intervention group
Group type: COMPARATOR
Intervention: Non-narrative video containing equivalent information about MC
Number of subjects: 396
Study 26934538 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐based multiple computer tailoring and counseling by a practice nurse (MTC)
Number of subjects: 414
Study 26934538 — intervention group
Group type: COMPARATOR
Intervention: Computer tailoring without counseling (MT)
Number of subjects: 414
Study 26934538 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 414
Study 24864592 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4mg
Number of subjects: 100
Study 24864592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4mg with Dexamethasone 8mg
Number of subjects: 100
Study 22169794 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily and Sorafenib 400 mg twice daily (MTD)
Number of subjects: 15
Study 20589888 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Unit Number Index (MUNIX) measurements
Number of subjects: 7
Study 20589888 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7
Study 18684771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) 500 microg
Number of subjects: 120
Study 18684771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) 375 microg
Number of subjects: 120
Study 18684771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) 250 microg
Number of subjects: 120
Study 17313008 — intervention group
Group type: EXPERIMENTAL
Intervention: Shu‐Mu point combination
Number of subjects: 90
Study 17313008 — intervention group
Group type: COMPARATOR
Intervention: Routine needling
Number of subjects: 90
Study 17313008 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Danazol)
Number of subjects: 90
Study 12927310 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogen rich diet
Number of subjects: 187
Study 12927310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (HRT)
Number of subjects: 187
Study 12927310 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 187
Study 10721508 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual physical therapy combined with supervised exercise
Number of subjects: 52
Study 10721508 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise alone
Number of subjects: 52
Study 8936356 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 2766 0.1 mg
Number of subjects: 124
Study 8936356 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 2766 0.4 mg
Number of subjects: 124
Study 8936356 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 2766 2 mg
Number of subjects: 124
Study 8936356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 1339125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide‐baking soda dentifrice
Number of subjects: 83
Study 1339125 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 83
Study 6388715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornithine-8-vasopressin injection
Number of subjects: 113
Study 31276540 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices (MAPs)
Number of subjects: 76
Study 31276540 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 76
Study 30341115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2g
Number of subjects: 320
Study 30341115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 25370439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 77
Study 25370439 — intervention group
Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SPT)
Number of subjects: 77
Study 22177939 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational sessions for asthma patients (60 minutes duration)
Number of subjects: 25
Study 22177939 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational sessions for COPD patients (60 minutes duration)
Number of subjects: 25
Study 20488250 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral graded activity (BGA)
Number of subjects: 149
Study 20488250 — intervention group
Group type: COMPARATOR
Intervention: Usual exercise therapy (UC; usual care)
Number of subjects: 149
Study 18797484 — intervention group
Group type: EXPERIMENTAL
Intervention: UKPDS risk engine
Number of subjects: 423
Study 18797484 — intervention group
Group type: EXPERIMENTAL
Intervention: NZGG-modified Framingham equation
Number of subjects: 423
Study 18797484 — intervention group
Group type: COMPARATOR
Intervention: Original Framingham equation
Number of subjects: 423
Study 18797484 — intervention group
Group type: COMPARATOR
Intervention: Combined UKPDS coronary heart disease plus stroke equations
Number of subjects: 423
Study 16013350 — intervention group
Group type: EXPERIMENTAL
Intervention: New balloon catheters
Number of subjects: 238
Study 16013350 — intervention group
Group type: COMPARATOR
Intervention: 1 time reused balloon catheters
Number of subjects: 238
Study 16013350 — intervention group
Group type: COMPARATOR
Intervention: 2 times reused balloon catheters
Number of subjects: 238
Study 16013350 — intervention group
Group type: COMPARATOR
Intervention: 3 times reused balloon catheters
Number of subjects: 238
Study 16013350 — intervention group
Group type: COMPARATOR
Intervention: Reused balloon catheters
Number of subjects: 238
Study 12776579 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEP formulation with lecithin
Number of subjects: 12
Study 12776579 — intervention group
Group type: COMPARATOR
Intervention: Marketed DHEP formulation without lecithin
Number of subjects: 12
Study 9873241 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with atopic dermatitis (AD)
Number of subjects: 40
Study 9873241 — intervention group
Group type: COMPARATOR
Intervention: Healthy infants (control group)
Number of subjects: 40
Study 7731275 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial and office systems intervention including full Medicare reimbursement for preventive care, regular prompting of physicians, new office system with nurses carrying out preventive procedures.
Number of subjects: 1914
Study 7731275 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group.
Number of subjects: 1914
Study 7731275 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial and office systems intervention.
Number of subjects: 1914
Study 1673937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole 1.0 g
Number of subjects: 100
Study 1673937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1673937 — intervention group
Group type: EXPERIMENTAL
Intervention: Both metronidazole and placebo groups combined
Number of subjects: 100
Study 7323709 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MIU of penicillin intravenously twice daily for 4 days, plus intraincisional injection of penicillin at wound closure
Number of subjects: 222
Study 7323709 — intervention group
Group type: COMPARATOR
Intervention: 2 MIU penicillin and 0.5 g streptomycin twice daily for 5 days (control group)
Number of subjects: 222
Study 7323709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 222
Study 7323709 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin therapy
Number of subjects: 222
Study 31261928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed nuts (250 kcal)
Number of subjects: 48
Study 31261928 — intervention group
Group type: COMPARATOR
Intervention: Pretzels (250 kcal)
Number of subjects: 48
Study 28100626 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 233
Study 28100626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 27484437 — intervention group
Group type: EXPERIMENTAL
Intervention: p-synephrine (S; 100 mg)
Number of subjects: 12
Study 27484437 — intervention group
Group type: EXPERIMENTAL
Intervention: p-synephrine + caffeine (SCF; 100 mg of p-synephrine plus 100 mg of caffeine)
Number of subjects: 12
Study 27484437 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study 24960324 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide amorphous calcium phosphate with fluoride (CPP‐ACPF)
Number of subjects: 1340
Study 24960324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF)
Number of subjects: 1340
Study 24960324 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1340
Study 24960324 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP‐ACPF
Number of subjects: 1340
Study 21627458 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Number of subjects: 60
Study 21627458 — intervention group
Group type: COMPARATOR
Intervention: Supragingival cleaning followed by scaling and root planing at 6 months
Number of subjects: 60
Study 19755410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg)
Number of subjects: 10
Study 19755410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17995584 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) with prednisolone for 6 months
Number of subjects: 20
Study 17995584 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) with prednisolone
Number of subjects: 20
Study 17995584 — intervention group
Group type: COMPARATOR
Intervention: Modified Ponticelli regimen (control)
Number of subjects: 20
Study 17995584 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil (compared to MMF)
Number of subjects: 20
Study 15045183 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pelvic pain syndrome
Number of subjects: 770
Study 11601768 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantec SC rotary instruments
Number of subjects: 20
Study 11601768 — intervention group
Group type: COMPARATOR
Intervention: Hand files and solvent
Number of subjects: 20
Study 9521541 — intervention group
Group type: COMPARATOR
Intervention: Paired association task
Number of subjects: 8
Study 9521541 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice reaction task
Number of subjects: 8
Study 8078529 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg daily
Number of subjects: 258
Study 8078529 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 15 mg daily
Number of subjects: 258
Study 8078529 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg daily
Number of subjects: 258
Study 8078529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 2462341 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (encainide, flecainide, moricizine, imipramine)
Number of subjects: 502
Study 2462341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 55647 — intervention group
Group type: EXPERIMENTAL
Intervention: B.C.G. treatment
Number of subjects: 48
Study 55647 — intervention group
Group type: COMPARATOR
Intervention: Control group (no B.C.G.)
Number of subjects: 48
Study 31707805 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg od plus single antiplatelet therapy (SAPT)
Number of subjects: 2124
Study 31707805 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg bid plus dual antiplatelet therapy (DAPT)
Number of subjects: 2124
Study 31707805 — intervention group
Group type: COMPARATOR
Intervention: Warfarin plus DAPT
Number of subjects: 2124
Study 28109423 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy proposals to restrict SNAP benefits based on nutrition quality (e.g., excluding sugary drinks)
Number of subjects: 0
Study 28109423 — intervention group
Group type: EXPERIMENTAL
Intervention: Updating the policies regulating SNAP benefits based on nutrition
Number of subjects: 0
Study 28109423 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities to restore trust between the public health and anti-hunger communities
Number of subjects: 0
Study 28109423 — intervention group
Group type: EXPERIMENTAL
Intervention: Optional SNAP program that includes both incentives and restrictions
Number of subjects: 0
Study 25862039 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B hemoperfusion (PMX HP)
Number of subjects: 243
Study 25862039 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 243
Study 23990895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) consisting of 12 weekly sessions of either cognitive therapy (n=41) or prolonged exposure (PE, n=49), starting 29.8±5.7 days after ED admission
Number of subjects: 957
Study 23990895 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Prolonged Exposure (PE) starting at 151.8±42.4 days (n=35)
Number of subjects: 957
Study 23990895 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 957
Study 21831508 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg p.o. three times daily)
Number of subjects: 100
Study 21831508 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) (600 mg p.o. three times daily)
Number of subjects: 100
Study 21831508 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 100
Study 19772608 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-Classic
Number of subjects: 0
Study 19772608 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-Fastrach
Number of subjects: 0
Study 18235936 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative embolization of the splenic artery
Number of subjects: 27
Study 18235936 — intervention group
Group type: COMPARATOR
Intervention: No preoperative embolization (control group)
Number of subjects: 27
Study 15112975 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 17
Study 15112975 — intervention group
Group type: COMPARATOR
Intervention: Cloxacillin
Number of subjects: 17
Study 11788129 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate treatment
Number of subjects: 0
Study 11788129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9750032 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of daily uracil/tegafur (UFT)
Number of subjects: 0
Study 9750032 — intervention group
Group type: COMPARATOR
Intervention: 6 cycles of cyclophosphamide/methotrexate/5-fluorouracil (CMF)
Number of subjects: 0
Study 7882815 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate supplementation
Number of subjects: 30
Study 7882815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3284310 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (MEX)
Number of subjects: 14
Study 3284310 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (Q)
Number of subjects: 14
Study 3284310 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (MEX-Q)
Number of subjects: 14
Study 3284310 — intervention group
Group type: COMPARATOR
Intervention: Drug free
Number of subjects: 14
Study 29746993 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise plus acupuncture
Number of subjects: 64
Study 29746993 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture alone
Number of subjects: 64
Study 26959668 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based problem-solving treatment (PST)
Number of subjects: 356
Study 26959668 — intervention group
Group type: COMPARATOR
Intervention: Education-only (EO)
Number of subjects: 356